Compare ADMA Biologics Inc (ADMA) vs Agora Inc (API) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Agora Inc — how do they compare? ADMA Biologics Inc trades at $9.98 (market cap $2.18B), while Agora Inc trades at $4.63 (market cap $385.97M). The key difference: ADMA Biologics Inc is far larger — about 5.6× Agora Inc's market cap, and Agora Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | API | |
|---|---|---|
Market Cap | $2.18B | $385.97M |
Sector | Health | Technology |
52-Week High | $20.38 | $5.26 |
52-Week Low | $7.60 | $3.24 |
Enterprise Value | $2.25B | $138.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
Agora, Inc. (API) trades at $4.46, up 7.47% today, with a bullish technical signal driven by moving averages. The company reported Q1 2026 EPS of $0.01, beating expectations, and shows improving fundamentals with 2025 revenue of $141.06M and net income of $9.53M. Recent news highlights its Q2 2026 earnings report scheduled for August 13, 2026.
Outlook is positive with analyst consensus at 60% buy, supported by a low P/B of 0.68 and strong cash flow growth. Risks include high P/E of 50.68 and competitive pressures in AI technology. The stock offers value potential if earnings growth continues, but volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Agora Inc
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
Read more on API →
